Feb 13 (Reuters)-
Brightpath Biotherapeutics Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2025 Dec 31, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 0 mln 0 mln 0 mln
(-62.5 pct) (+33.3 pct) (-87.6 pct)
Operating loss 956 mln loss 815 mln loss 1.18
Recurring loss 952 mln loss 812 mln loss 1.16
Net loss 955 mln loss 815 mln loss 1.17
EPS loss 9.07 yen loss 10.30 yen loss 12.88 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Brightpath Biotherapeutics Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T